Literature DB >> 18757470

Gamma knife radiosurgery for uveal melanoma: 12 years of experience.

G Modorati1, E Miserocchi, L Galli, P Picozzi, P Rama.   

Abstract

AIM: To present our treatment protocol and evaluate the results of Gamma knife radiosurgery (GKR) in treating patients with uveal melanoma.
METHODS: Seventy-eight consecutive patients with uveal melanoma underwent stereotactic radiosurgery (radiation dose 30-50 Gy) with a Leksell Gamma-Knife at the San Raffaele University Hospital, Milan, Italy between 1994 and 2006. The main outcome measures evaluated were: survival rate, local tumour control, eye retention rate, visual acuity and treatment-related complications.
RESULTS: Survival rate was 88.8% at 3 years and 81.9% at 5 years. Local tumour control was achieved in 91.0% of patients. The median tumour thickness reduction after treatment was 1.96 mm (p<0.0001) (-32.1%). The eye retention rate was 89.7%. A significant relative reduction of visual acuity was observed during follow-up. The most frequent treatment-related complications were: exudative retinopathy (33.3%), neovascular glaucoma (18.7%), radiogenic retinopathy (13.5%) and vitreous haemorrhages (10.4%).
CONCLUSION: GKR can be considered an alternative to enucleation for the treatment of choroidal melanomas.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18757470     DOI: 10.1136/bjo.2008.142208

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  17 in total

1.  Stereotactic radiotherapy for choroidal melanomas by means of HybridArc™ : Physics and technique of linac-based photon beam therapy.

Authors:  Markus Wösle; Lothar Krause; Shanthala Sreenivasa; Dirk Vordermark; Ilja F Ciernik
Journal:  Strahlenther Onkol       Date:  2018-08-16       Impact factor: 3.621

2.  3D WrapTM Ultra-Widefield Reconstruction in Stereotactic Radiosurgery for Choroidal Melanoma.

Authors:  Maria Vittoria Cicinelli; Alessandro Marchese; Francesco Bandello; Giulio Maria Modorati
Journal:  Ocul Oncol Pathol       Date:  2019-06-12

Review 3.  [CyberKnife®: new treatment option for uveal melanoma].

Authors:  J M Mor; R Semrau; W Baus; K R Koch; F Schaub; C Cursiefen; S Marnitz; L M Heindl
Journal:  Ophthalmologe       Date:  2018-04       Impact factor: 1.059

Review 4.  Emerging treatments for choroidal metastases.

Authors:  Connie J Chen; Allison N McCoy; Julie Brahmer; James T Handa
Journal:  Surv Ophthalmol       Date:  2011 Nov-Dec       Impact factor: 6.048

5.  Gamma-knife-based stereotactic radiosurgery for medium- and large-sized posterior uveal melanoma.

Authors:  Ahmet M Sarici; Halit Pazarli
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-09-04       Impact factor: 3.117

6.  Gamma Knife Radiosurgery for Uveal Melanoma: A Retrospective Review of Clinical Complications in a Tertiary Referral Center.

Authors:  Giulio Maria Modorati; Roi Dagan; Lauge Hjorth Mikkelsen; Simon Andreasen; Alfio Ferlito; Francesco Bandello
Journal:  Ocul Oncol Pathol       Date:  2019-09-03

7.  Malignant melanoma and radiotherapy: past myths, excellent local control in 146 studied lesions at Georgetown University, and improving future management.

Authors:  Pooya Jahanshahi; Nadim Nasr; Keith Unger; Ali Batouli; Gregory J Gagnon
Journal:  Front Oncol       Date:  2012-11-15       Impact factor: 6.244

Review 8.  Current and emerging treatment options for uveal melanoma.

Authors:  Patricia Rusa Pereira; Alexandre Nakao Odashiro; Li-Anne Lim; Cristina Miyamoto; Paula L Blanco; Macanori Odashiro; Shawn Maloney; Dominique F De Souza; Miguel N Burnier
Journal:  Clin Ophthalmol       Date:  2013-08-22

Review 9.  Uveal Melanoma: Current Trends in Diagnosis and Management.

Authors:  Berçin Tarlan; Hayyam Kıratlı
Journal:  Turk J Ophthalmol       Date:  2016-06-06

Review 10.  Local treatment failure after globe-conserving therapy for choroidal melanoma.

Authors:  Melinda Y Chang; Tara A McCannel
Journal:  Br J Ophthalmol       Date:  2013-05-03       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.